Calcium and cardiovascular risk: what the evidence shows

← Back to articles

Concerns about cardiovascular harm from calcium supplementation surfaced in 2010 and have never fully resolved. A decade and a half of meta-analyses have produced a genuinely split literature: some pooled analyses find a small excess of myocardial infarction with calcium taken on its own, while the most recent syntheses find no significant association at all. What follows is what the actual trials and meta-analyses show — not a settled verdict, but a small and contested signal that points toward a few sensible, low-cost precautions.

How the controversy started

The alarm was raised by a 2010 patient- and trial-level meta-analysis from Mark Bolland and colleagues, published in the BMJ. Pooling 15 randomized, placebo-controlled trials of calcium supplements (without coadministered vitamin D), they found that calcium was associated with an increased risk of myocardial infarction: a hazard ratio of 1.31 (95% CI 1.02–1.67) in the five studies with individual-patient data, and a relative risk of 1.27 (95% CI 1.01–1.59) in the trial-level analysis of 11,921 participants [1]. Increases in stroke and the composite of MI/stroke/sudden death were smaller and not statistically significant. A companion review summarised the effect as a 27–31% relative increase in MI risk and argued the role of calcium supplements in osteoporosis warranted reassessment [2].

The Women's Health Initiative and its reanalysis

The single largest trial complicates the picture. The Women's Health Initiative Calcium/Vitamin D (WHI CaD) study randomized 36,282 postmenopausal women to 1,000 mg calcium carbonate plus 400 IU vitamin D3 daily or placebo and, over roughly 7 years, found no increase in coronary heart disease (HR 1.04, 95% CI 0.92–1.18) or stroke (HR 0.95, 95% CI 0.82–1.10) [3]. Bolland's group argued this null result was diluted by the trial's allowance of personal calcium use, and reanalysed the limited-access dataset: among the 46% of women not already taking calcium at baseline, hazard ratios for cardiovascular events ranged from about 1.13 to 1.22, and a meta-analysis incorporating that subset put the MI relative risk around 1.24 (95% CI 1.07–1.45) [4]. Critics counter that this is a post-hoc subgroup of a trial that was negative as designed — a reasonable hypothesis, but not the same as a prespecified positive result.

What the more recent meta-analyses find

The evidence has not converged. A 2019 systematic review and meta-analysis pooling 16 RCTs and 26 cohort studies reported that calcium supplements raised coronary heart disease risk by about 8% overall, and that calcium taken alone raised myocardial-infarction risk by roughly 21% (RR 1.21, 95% CI 1.08–1.35), while dietary calcium showed no such association [5]. But a 2023 meta-analysis of 12 RCTs reached the opposite conclusion: calcium supplementation was not significantly associated with myocardial infarction, stroke, heart-failure admission, or cardiovascular or all-cause mortality, and subgroup analyses by calcium-alone versus calcium-plus-vitamin-D, sex, follow-up, and region did not change that result [6]. The honest summary is that whether a small harm exists depends heavily on which trials are pooled and how — a hallmark of an effect that is, at most, small.

The mechanistic question

The biological rationale for a calcium-alone effect is that supplements produce a sharp post-dose rise in blood calcium that food does not, and the hypothesis is that these transient spikes could nudge vascular calcification, platelet reactivity, or coagulation in an unfavourable direction — possibly via calcium-sensing receptors on vascular cells [2]. This is plausible and consistent with epidemiology linking higher circulating calcium to cardiovascular disease, but it remains a mechanism in search of a definitive outcome trial rather than established fact.

Why vitamin D co-administration keeps coming up

A recurring theme is that the clearest signals appear with calcium taken alone, not with calcium combined with vitamin D. The WHI CaD trial used the combination and was null overall [3]; meta-analyses that separate the two consistently find the harm concentrated in monotherapy [4][5]. Whether that reflects a true protective interaction or simply different trial populations is unresolved, but it underlies the practical advice that, if a supplement is needed, the combined product is the more defensible choice.

Population vs individual decision making

Even on the least favourable reading, the absolute risk is small, and it has to be weighed against calcium's modest skeletal benefit. A wider review by the same group that raised the alarm concluded that calcium supplements reduce total fractures by only 0–10% while increasing gastrointestinal side effects, kidney stones (about 17%), and — on their analysis — myocardial infarction by 20–40%, and argued the risk–benefit balance for routine supplementation is unfavourable [7]. Others, citing the null 2023 meta-analysis, regard that conclusion as overstated [6]. Where they agree: prioritise dietary calcium, reserve supplements for people who genuinely cannot reach roughly 1,000–1,200 mg/day from food, keep individual doses modest (around 500 mg, with meals), and favour a combined calcium–vitamin D product over calcium alone.

Sources

1. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. "Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis." BMJ, 2010;341:c3691. PMID 20671013. DOI: 10.1136/bmj.c3691.
2. Reid IR, Bolland MJ, Avenell A, Grey A. "Cardiovascular effects of calcium supplementation." Osteoporosis International, 2011;22(6):1649–1658. PMID 21409434. DOI: 10.1007/s00198-011-1599-9.
3. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, et al. "Calcium/vitamin D supplementation and cardiovascular events." Circulation, 2007;115(7):846–854. PMID 17309935. DOI: 10.1161/CIRCULATIONAHA.106.673491.
4. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. "Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis." BMJ, 2011;342:d2040. PMID 21505219. DOI: 10.1136/bmj.d2040.
5. Yang C, Shi X, Xia H, Yang X, Liu H, Pan D, Sun G. "The Evidence and Controversy Between Dietary Calcium Intake and Calcium Supplementation and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Cohort Studies and Randomized Controlled Trials." Journal of the American College of Nutrition, 2020;39(4):352–370. PMID 31625814. DOI: 10.1080/07315724.2019.1649219.
6. Sim MG, Teo YN, Teo YH, Syn NL, Li TYW, Yeo LLL, Kong WKF, et al. "Association Between Calcium Supplementation and the Risk of Cardiovascular Disease and Stroke: A Systematic Review and Meta-Analysis." Heart, Lung & Circulation, 2023;32(10):1230–1239. PMID 37743221. DOI: 10.1016/j.hlc.2023.07.008.
7. Reid IR, Bristow SM, Bolland MJ. "Calcium supplements: benefits and risks." Journal of Internal Medicine, 2015;278(4):354–368. PMID 26174589. DOI: 10.1111/joim.12394.